Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the Central Nervouse System (CNS). The goal of this study was   more »

Thank you for your comment on my blog. I did not write that article. I reported it from Associated Press - Jun. 29, 2009. I put Associated Press - Jun. 29, 2009 on the bottom of the article to indicate that I did not write it. But   more »

Prednisone or acetaminophen may significantly control flulike symptoms (FLSs) in patients with relapsing multiple sclerosis (MS) who are treated with interferon (IFN) beta-1a, according to a study presented here at the   more »

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart(TM) for the self-administration of Rebif(R) (interferon beta-1a), the company's disease-modifying   more »

Patients with multiple sclerosis (MS) who adhere to their treatment with interferon (IFN) beta-1a without interruption have lower relapse and progression rates than patients who do not adhere to their medication as regularly   more »

company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives outside the U.S., had been using Tysabri for 30 months. Three of the ten   more »

A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European   more »

Patients with multiple sclerosis who are treated with a cumulative dose of 82 mg/m[2 of Mitoxandrone (MTX) are at a 2.7 higher risk of developing acute leukemia (AL), according to a late-breaking abstract presented on April 30   more »

Emphasis on the reduction of relapses as early as possible is important because you may not always recover your previous level of functioning after a relapse. Quite often, irreversible   more »

The risk of developing progressive multifocal leukoencephalopathy (PML), a viral brain infection, in patients with multiple sclerosis (MS) taking the drug natalizumab (Tysabri) appears to be much lower - and the infection   more »

with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent   more »

New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) may offer sustained protection from neuronal/axonal injury. This protective effect was reflected biologically by a significant   more »

Health Canada has approved an expanded indication for glatiramer acetate injection (Copaxone) to include the treatment of patients who have experienced a single demyelinating event, accompanied by abnormal magnetic resonance imaging (MRI)   more »

Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri®), a drug that   more »

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced five-times as many multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) were free from disease activity versus placebo in the overall patient population. Results   more »